Research Areas
- Breast Cancer
- Prostate Cancer
- Health Disparities
- Chemical Biology
Scientific Achievements
- Developed and characterized the anti-cancer efficacy of the ADRM1 inhibitor Up284 as a potential therapeutic strategy for QNBC
- Identified mitochondrial changes that distinguish tumors from African American patients from those of European American patients.
- Advanced next-generation therapeutics targeting tumor-associated macrophages.
- Involved in the Minority Biospecimen/Biobanking Geographic Management Program (BMaP) and the Prostate Cancer Transatlantic Consortium (CaPTC).
Funding
RCMI Funding:
- 5U54MD007585, NIH/NIMHD
Other funding obtained with RCMI support:
- 1UG3HG013553-01, National Human Genome Research Institute
- 1R41CA257110-01, NCI
Scientific Advance
Novel 3,19-(N-Phenyl-3-(4-fluorophenyl)-pyrazole) Acetal of Andrographolide Promotes Cell Cycle Arrest and Apoptosis in MDA-MB- 231 Breast Cancer Cells
Published in, Pharmaceuticals 2025, 18(7), 1026; PMCID: PMC12298351.
Published in, Pharmaceuticals 2025, 18(7), 1026; PMCID: PMC12298351.
The synthesized 3,19-(N-phenyl-3-aryl-pyrazole) acetals of andrographolide and isoandrographolide exhibited promising anticancer properties, potential as a lead candidate for further anticancer drug development.
Whole-exome sequencing of Nigerian benign prostatic hyperplasia reveals increased alterations in apoptotic pathways Published in Prostate. 2024 Apr;84(5):460-472. PMCID: PMC10922327.
This work is the first to examine genomic sequencing in Nigerian BPH patients and provides data that fill known gaps in the understanding BPH and how it impacts men of African ancestry.
NIH/NIMHD #U54MD007585
